Stories

FY 2025 was a year of strong execution and robust performance across all therapeutic areas, driving significant topline growth and reinforcing the company’s strategic momentum. Total sales grew 10.9% at constant exchange rates (CER), supported by a solid 7.5% growth in Q4.

New in our A Life in Science series, we hear from Eli Leo, Early Development Asset Lead, about how teamwork, creativity, and even failure fuel progress in research. From seeing herself as a conductor guiding scientists like an orchestra to learning from the 98% of experiments that do not succeed, she shows how resilience and collaboration create meaningful breakthroughs for patients.

Before a medicine reaches patients, its promise must be measured against its risks. For Lineu Domit, safety physician in Ipsen’s Global Patient Safety team, this balance is the essence of early development.

As we prepare to mark World Cancer Day, which continues its three-year commitment to the powerful global theme of “United by Unique”, Ipsen acknowledges the immense, global challenge that cancer presents.

Together for the Climate: Ipsen Strengthens Its Climate Commitment with CDP A-List Recognition and SBTi Approval